American supplier of scientific instrumentation, reagents and consumables, and software services, Thermo Fisher Scientific has opened a new sterile drug facility in Singapore that will better enable customers to deliver new medicines and vaccines in the Asia-Pacific market. 

The new facility also marks a significant milestone and investment in pandemic preparedness for Singapore, which is fast emerging as a biomedical hub in the Asia-Pacific region.

Established with assistance from the Singapore Economic Development Board (EDB), in alignment with the government’s investment in preparedness for future health emergencies, the current Good Manufacturing Practices (cGMP) facility will provide rapid vaccine fill-finish capabilities along with Thermo Fisher’s end-to-end pharmaceutical development and manufacturing services.

The new facility includes a high-speed, fully automated aseptic fill-finish line for small and large molecules. This strategic investment in Singapore complements new research capabilities at Thermo Fisher Scientific's Customer Experience Center and Bioprocess Design Center, two other operational lab facilities that showcase the latest bioprocessing, life science, and analytical technologies. 

In total, over 2,000 company employees are contributing to Singapore’s evolution as a biomedical hub in the Asia-Pacific region.